Select Sires and Infigen Sign Agreement For Future Cloning of Selected Bulls
DEFOREST, Wis., and PLAIN CITY, Ohio, Aug. 8, 2000 — Select Sires Inc.,
the nation’s leading supplier of cattle genetics, announced that it
has signed an agreement with Genmark®, a division of Infigen Inc.,
for future cloning of selected bulls. The agreement will allow Select
Sires to clone a bull whose demand exceeds production capabilities,
assuring cattle producers worldwide of an adequate supply of semen
from its top bulls.
Genmark is the agricultural marketing division of Infigen, the world
leader in nuclear transfer cloning, cattle gene mapping, cryopreservation
and other related genomic technologies.
In discussing the application of the cloning technology, Select Executive
Vice President and General Manager David Thorbahn explained, "Elite sires
drive genetic improvement in the cattle industry. History is littered with
great sires whose semen production limitations diminished their impact and
value to producers. Infigen's technology provides us an exciting opportunity
to solve this problem. When Select Sires identifies a genetically elite bull
whose semen supply is limited, we are poised to move quickly, if we so choose."
Infigen has combined research in farm animal genetics and reproduction
processes to develop and provide commercial applications and products to
the human healthcare and animal agriculture fields. The company was formed
in 1997, the same year it produced Gene, the world's first cloned bovine
from a non-embryo-derived cell.
"Genmark’s agricloning opens up a whole new world of opportunities for
today's cattle producers," says Jesús Martínez, vice president of marketing
for Infigen. "Genmark cloning technology, along with our other reproductive
services and genetic tests, will offer producers ways to become more
efficient, productive and profitable."
Infigen is a privately held biotechnology company with core competencies
in nuclear transfer cloning, cattle gene mapping, semen sexing and
cryopreservation. It currently employs 30 research and administrative
support personnel and has other research and development collaborations
with Pharming, NV, Leiden, The Netherlands, and Imutran, Ltd., Cambridge,
England, a wholly owned subsidiary of Novartis Pharma AG, Basel, Switzerland.
Select Sires’ alliance with Infigen fits with the company's pledge to produce
and deliver superior genetics of high fertility at reasonable prices to
dairy and beef producers. Select Sires is committed to aggressively pursuing
technological advances that benefit the farmer-patrons of its 10 farmer-owned
and controlled cooperatives.
Copyright 1996-2002 Select Sires Inc. Last updated 15-Jan-2002.
|